PREDICTION OF POTENTIAL INHIBITORS SIMILAR TO REMDESIVIR (GS-5734) AGAINST 7BTF SARS COV 2 RNA DEPENDENT RNA POLYMERASE – AN IN-SILICO APPROACH

PREDICTION OF POTENTIAL INHIBITORS SIMILAR TO REMDESIVIR (GS-5734) AGAINST 7BTF SARS COV 2 RNA DEPENDENT RNA POLYMERASE – AN IN-SILICO APPROACH

Akila *, B. Pooja and R. Sharmila

Department of Biotechnology and Bioinformatics, Bishop Heber College (Autonomous), Tiruchirappalli, Tamil Nadu, India.

ABSTRACT: The novel Corona Virus Disease - 19 (COVID-19) is a Contagious disease spreading among Animals and Humans, a Severe Acute Respiratory Syndrome CoronaVirus-2 (SARS CoV2). The First case was identified in Wuhan, China as the disease has unfolded worldwide to the continuing pandemic. It created more infected cases and deaths worldwide, creating an urge for newer drugs of manipulate the Ongoing Pandemic and address the contemporary state of affairs. Remdesivir (GS-5734) has been recognized because the first authorized remedy for intense COVID-19 and has also been recognized to be a novel nucleoside an a log with a large antiviral activity spectrum among RNA viruses which include ebolavirus (EBOV) and the respiratory pathogens Middle East breathing syndrome coronavirus (MERS-CoV), SARS-CoV and SARS-CoV-2. Being first defined in 2016, the drug was derived from an Antiviral library of small molecules intended to target emerging pathogenic RNA viruses. Remdesivir has been discovered to lessen the time to restoration of hospitalized patients who require supplemental oxygen and has a high-quality effect on mortality results whilst having a positive safety profile. 7BTF-SARS-CoV-2, an RNA-structured RNA polymerase, has been discovered as an ability goal gambling a vital role within the viral lifecycle. This study aims at developing an inhibitor using Virtual screening of Compounds similar to Remdesivir (GS-5734). Molecular Docking studies have been performed, and quantitative structure-activity relationship (QSAR) studies have been performed in opposition to compounds similar to Remdesivir. Their inhibitory activity was studied and justified for structurally similar compounds.

Keywords: COVID-19, Corona Virus, Remdesivir, GS-5734, Molecular Docking, QSAR

INTRODUCTION: The world is dealing with an exceptional clinical emergency without an efficacious remedy for the SARS-CoV2 virus that causes Covid-19. Two drugs that have been used for supplemental indications inside the beyond, hydroxychloroquine (HCQ) and remdesivir (RDV) are in a quest to be repurposed to treat Covid-19.

Both drugs were accepted for emergency use by the USA Food and Drug Administration. In this evaluation, we certainly analyze the identification and activities related to these drugs as potential therapies for Covid-19 and problems that require deep attention within the global clinical network worried about using those as anti-Covid -19 drugs.

Given the sudden and vital nature of the sickness and its high fee of contamination, as well as the spread and time involved in developing and advertising a new, more secure, and more powerful drug, researchers around the sector are trying to re-invent the popular Covid-19 healing drug. As SARS-CoV-2, the causative agent of Covid-19, with a comparable genetic predisposition to acute respiration syndrome (SARS-CoV) and Middle East breathing syndrome (MERS CoV), tablets used to deal with SARS and MERS have also been reviewed to determine the volume in their interest as compared to SARS-CoV-2. Similarly, an article from China posted on February 4, stated that chloroquine (CQ), hydroxychloroquine (HCQ), and remdesivir (RDV) efficaciously inhibited SARS-CoV-2 infection. Chloroquine (CQ) has been used for over 70 years in the treatment of situations such as CQ-malaria-sensitive, amoebiasis, systemic lupus erythematosus (SLE), and rheumatoid arthritis (RA). No vast facet outcomes had been found whilst taken in prescribed quantity; however, chloroquine is related to ophthalmologic reactions at better tiers, even though no extreme cardiac outcomes were stated, including arrhythmias and CQ.

Additional studies involving 317 SLE sufferers have advised that CQ additionally plays a defensive role within the unexpected upward push in cardiovascular arrhythmias and motor impairment. Hydroxy Chloro Quine, a spinoff determined underneath the poisonous of CQ, has been used to deal with conditions that includes RA, pediatric idiopathic arthritis, and Sjogren's syndrome. The toxicity profile of HCQ may be very much like CQ. Also, HCQ has been categorized as safe throughout pregnancy. Due to its low toxicity and cost-effectiveness, HCQ was accredited to be used in Covid-19 treatment.

However, a pilot observation published in May 2020 states that HCQ administration is no longer associated with a widespread boom or decrease in the last lodge or mortality main to the search for a higher drug. Consequently, Due to the uncontrolled boom and the non-stop boom of COVID-19 in January and February 2020, tremendous efforts have been made to identity of antiviral retailers that work towards COVID-19. Nucleoside/nucleotide analogs were identified as one of the most promising antiviral drugs, and sizeable drug discovery emerged in this segment today as the basis for a remedy against numerous herpesviruses, HIV, hepatitis B virus (HBV), and hepatitis C virus (HCV). Remdesivir or GS-5734 is a prodrug of nucleoside analog with precise antiviral hobby against an expansion of various RNA viruses, together with SARS-CoV and Middle East breathing coronavirus (MERS-CoV). Initial research with remdesivir cells confirmed antiviral activity towards the virus SARS-CoV-2. Hence this study aimed at Predicting the efficacious capacity inhibitor with the aid of screening compounds similar to Remdesivir against 7BTF-SARS-CoV-2 RNA-established RNA polymerase, a potential target in Severe Acute Respiratory Syndrome CoronaVirus-2 (SARS CoV2) inflicting Covid-19, leading to the Ongoing Pandemic - an in-silco Approach. The modern COVID-19 pandemic - seemingly global public health trouble has been a fast development in what we understand approximately pathogens, how they infect cells, and motive ailment and clinical symptoms of the ailment.

As an end result of the rapid transfer, international locations around the sector need to boom attention to disorder tracking structures and boom national readiness and responsiveness, including establishing faster reaction groups and improving the ability of the countrywide laboratory gadget ¹. On December 31, 2019, the China Health Authority notified the World Health Organization (WHO) of several cases of unknown etiology pneumonia in Wuhan City in Hubei province in critical China. Cases were suggested on December 8, 2019, and plenty of patients had been running or residing near the neighborhood of Huanan Seafood Wholesale Market even though some authentic instances were unavailable on this marketplace ².

The pathogen was identified as additionally renamed excessive acute respiratory syndrome coronavirus 2 (SARS-CoV-2) via the Coronavirus Study Group ^4, and the ailment was named coronavirus disease 2019 (COVID-19) with the aid of WHO. As of January 30, 7736 it's been shown that 12,167 suspected cases have been suggested in China and 82 confirmed instances have been located in 18 other countries ⁵. On the equal day, WHO announced the outbreak of SARS-CoV-2 as Public Health Emergency of International Concern (PHEIC) ⁵. According to the Chinese National Health Commission, the mortality rate among China's assured fees turned to 2.1% when you consider that February four ⁶ and the mortality fee turned to zero.2% amongst cases out of doors China ⁷. Among hospitalized patients, the mortality rate became between eleven% and 15% ^{8, 9}. COVID-19 is moderately inflamed with a excessive mortality price; however, statistics on public reviews and posted courses is increasing swiftly. This overview aims to summarize the modern know-how of COVID-19, which include the causative agent, the pathogenesis of the sickness, the analysis and treatment of cases, and management and prevention strategies.

Drugs are tested according to previous studies on treating SARS and MERS ⁵⁰. Overall, there is no conclusive proof that these antibodies can drastically improve scientific outcomes. Antimicrobials and oseltamivir blended with antibiotics have additionally been used to deal with COVID-19 sufferers ⁸. Remdesivir, designed for the Ebola virus, has been used to deal with COVID-19 instances imported into america ⁵¹. A short record of the combination therapy of Lopinavir / Ritonavir, Arbidol and Shufeng Jiedu Capsule (SFJDC), a traditional Chinese remedy, has proven clinical advantage in 3 out of 4 sufferers with COVID-19 ⁵². Ongoing scientific trials analyze the protection and efficacy of lopinavir-ritonavir and interferon-α 2b in patients with COVID-19 ⁵⁵. Remsedivir, a comprehensive antivirus, has shown in-vitro and in-vivo overall performance compared to SARS-CoV-2 and has additionally begun its trials ^{52, 53}. In addition, present viral marketers have proposed different potential drugs ^{56, 57}.

Due to the out-of-control increase and the non-stop increase of COVID-19 in January and February 2020, considerable efforts have been made to identify antiviral marketers that oppose COVID-19. Nucleoside/nucleotide analogs were diagnosed as one of the most promising antimicrobial capsules. A huge drug discovery emerged today as the basis for treatment in opposition to numerous herpesviruses, HIV, hepatitis B (HBV), and hepatitis C (HCV). Remdesivir or GS-5734 is a prodrug of nucleoside analog with precise antiviral activity in opposition to the diffusion of various RNA viruses, SARS-CoV, and the Middle East respiratory system coronavirus (MERS-CoV). Initial studies executed with remdesivir also confirmed antiviral activity towards the virus SARS-CoV-2. In the absence of effective healing procedures towards COVID-19, remdesivir has been used less sensitively. Recent preliminary data from a randomized controlled scientific trial confirmed that remdesivir reduced restoration time in patients with COVID-19, mainly to EUA and Drug Administration (FDA) approval days after discharge.

For the primary time in the media on the National Institute of Allergy and Infectious Diseases (NIAID). On July 3, the European Medicines Agency (EMA) conditional legal advertising of remdesivir, now the first antiretroviral treatment for COVID-19, concludes with a complete review of results from pre-studies, remedy studies, and its medical significance. Comparing in-vitro results of Remdesivir to numerous CoVs, along with SARS-CoV-2 and its effectiveness has been notably studied. Animal studies involving non-human MERS-CoV models and greater lately, SARS-CoV-2 aid its effectiveness, especially when given at an early level of the ailment. Remdesivir reduces the recuperation time by 31%, which is a modest, however clean side impact of the remedy. In addition to those beneficial consequences on sufferers, it may also help to lessen the number of unwell days and the fantastic consequences on hospital expenses and strength problems that have arisen through the COVID-19 epidemic in numerous countries. Further drug efforts are needed to make the drug accessible to those who cannot be excluded.

Recently, it was announced that a segment 1 trial with remdesivir inhalation is deliberate and has already been approved through the FDA. With the plan already being authorized by the FDA and the idea of screening compounds just like Remdesivir brought about the identification of Potential inhibitors, these Insilco recommendations tend to be beneficial in helping to SARS CoV2 experimental Drug Discovery ⁶¹.

MATERIALS AND METHODS:

The Target Identification: The Protein responsible for SARS CoV2 Infection COVID-19 was searched through literature and 7BTF-SARS-CoV-2, an RNA-dependent RNA polymerase, has been found as a potential target playing a vital role in the viral lifecycle. The Structure was retrieved from Protein Data Bank (PDB).

Selection of Ligands: The large antiviral activity of Remdesivir is superior by using its efficacy, and to this point, it has shown fine in-vitro interest against Arenaviridae, Flaviviridae, Filoviridae, Paramyxoviridae, Pneumoviridae and Coronaviridae families of viruses playing a vital interest in regeneration as a probable remedy for COVID-19. Remdesivir has been licensed as a non-binding RdRp terminator from SARS-CoV-2 and SARS-CoV and its associated MERS-CoV and has been investigated in numerous medical trials of COVID-19. The recent chemical evaluation found out that in SARS-CoV-2, Remdesivir-TP induces the elimination of RNA synthesis in three positions (+3). This approach turned into nearly the same as SARS-CoVRdRps and MERS-CoV.

In the long run, early termination of RNA synthesis eliminates the extra transcription and translation tactics required for producing new virions. Passing the cell side with remdesivir is aided through the part of the prodrug attached to the nucleoside content material and upon coming into the target cellular, pronucleotide continues with other phosphorylation steps to end up an energetic triphosphate metabolite that correctly inhibits the replication of viral RNA and was retrieved from PubChem Database.

Virtual Screening: Virtual screening (VS) is a computational approach used in drug discovery to search libraries of small molecules to perceive structures that might most likely bind to a drug target, generally a protein receptor or enzyme. It has been defined because the "mechanically evaluating very huge libraries of compounds" uses packages and has largely been a number specializing in how the massive chemical space of over 1060 doable compounds can be filtered to a plausible variety that may be synthesized, purchased, and examined.

However, searching the complete chemical universe can be a theoretically exciting hassle, greater practical VS eventualities awareness on designing and optimizing targeted combinatorial libraries and enriching libraries of available compounds from in-residence compound repositories or supplier offerings. As the method's accuracy has extended, virtual screening has become a productive part of the drug discovery procedure. Virtual screening may be used to select in-house database compounds for screening, pick compounds that may be bought externally and choose which compound needs to be synthesized next. The virtual screening method changed into done and 18 compounds, at least forty%, just like Remdesivir (GS-5734), have been determined and retrieved from the ZINC database. The compounds with at least 40% similarity to Remdesivir (GS-5734) retrieved from ZINC database includes, ZINC000166442021, ZINC000166442088, ZINC001772647544, ZINC001772647545, ZINC001772610688, ZINC001772610689, ZINC001772635410, ZINC001772635718, ZINC001772612042, ZINC001772612043, ZINC001772620192, ZINC001772620193, ZINC000103270228, ZINC000103270230, ZINC000103262203, ZINC000103262205, ZINC000103270205, ZINC000103270207.

Molecular Docking: Molecular Docking was carried out using the Software AutoDockVina Based on the obtained results from Molecular docking, Three Compounds were found to show better Binding Affinities in comparison to Remdesivir, and those three compounds, along with their dock scores include, including ZINC001772610689 (8.6), ZINC001772610688 (-8.4), ZINC001772612043 (-7.6).

The Binding Conformations of these compounds in active sites were analyzed, and the docking results were interpreted based on the docking score, with information on Binding Affinity and mode of interaction with key Amino Acid Residue in Active sites. The results were also visualized using PyMOL – a molecular visualization tool.

QSAR Studies and ADMET Properties Calculation: QSAR studies were performed, and important molecular properties (logP, polar surface area, number of hydrogen bond donors and acceptors, and others), as well as prediction of bioactivity score for the most important drug targets (GPCR ligands, kinase inhibitors, ion channel modulators, nuclear receptors). The Chemical Properties and their BioActivity scores were calculated for the Ligand complexes, and the ADMET properties were calculated using the tool ADMETsar-2.0.

FIG. 1: STRUCTURE OF 7BTF SARS-COV-2 RNA-DEPENDANT RNA POLYMERASE IN COMPLEX WITH COFACTORS IN REDUCED CONDITION

FIG. 2: 2D STRUCTURE OF REMDESIVIR (GS-5734) RETRIEVED FROM PUBCHEM DATABASE

FIG. 3(A): LIGAND ZINC001772610689 WITH BINDING AFFINITY - 8.6

FIG. 3(B): BINDING OF ZINC001772610689 TO 7BTF – SARS COV-2 RNA DEPENDANT RNA POLYMERASE

FIG. 4(A): LIGAND ZINC001772610688 WITH BINDING AFFINITY - 8.4

FIG. 4(B): BINDING OF ZINC001772610688 TO 7BTF – SARS COV-2 RNA DEPENDANT RNA POLYMERASE

FIG. 5(A): LIGAND ZINC001772612043 WITH BINDING AFFINITY - 7.6

FIG. 5(B): BINDING OF ZINC001772612043 TO 7BTF – SARS COV-2 RNA DEPENDANT RNA POLYMERASE

Conclusions and Future Perspective: The outbreak of the COVID-19 virus has challenged financial, medical, and social infrastructure Worldwide and posed a serious danger to humanity. There is a pressing need for new drugs to deal with this pandemic. Many researchers are operating on it to locate a likely remedy; however, we're far from finding the proper result. Research strategies on the side of effective Insilco gear and strategies has shown to have the capability to broaden novel inhibitors. The computational strategies' quick-time period requirements contribute to the high cost of available tablets to pick out ability drugs for novel sicknesses and to expect unfavourable drug aspect effects. In the contemporary venture, we have presented a chain of studies related to identification, Virtual Screening, Molecular Docking, ADMET prediction and QSAR. Here, we have mostly focused on studies concentrated on 7BTF - SARS CoV2 RNA primarily based on RNA polymerase. After many years of studies into powerful antiretroviral drugs, Remdesivir is the first nucleoside analogue that may be used to deal with respiratory infections. Given the integral scientific outcomes, and thinking about its safe safety profile and the shortage of alternative therapies to COVID-19, Remdesivir will be widely used out of the doors of traditional medical trials or empathy applications.

However, anti-retroviral treatment will now not be sufficient to keep the lives of COVID-19 patients reliably or to deal with the severe public health problems resulting from the continued COVID-19 epidemic. Antiviral treatment in hospitalized sufferers cannot prevent the virus from transmitting to the network and cannot adjust the pathophysiological tactics that exist already at the time of prognosis. Preferred prophylactic measures could be best in decreasing COVID-19 morbidity and mortality and economic influences. The prophylactic use of remdesivir may be effective because it absolutely protects from medical contamination caused by MERS-CoV.

Prophylactic results are also recognized from other tablets acting as neuraminidase inhibitors that may save from flu infection and be used as put-up exposition prophylaxis. However, the prophylactic use of remdesivir is frequently hampered by means of oral pain and the absence of an oral system. Additional efforts to develop the drug are had to make the drug available to human beings now play a critical position. The healing efficacy of remdesivir may be stronger with the addition of other antivirals or immunomodulatory agents. It has lately been shown that glucocorticoids can improve medical consequences in the instances of COVID-19 in excessive and touchy cases. However, blended therapy should be used cautiously, as drug interactions are feasible.

In-vitro, remdesivir acts as a substrate or inhibitor of several drug enzymes (e.g., CYP3A4), that can affect the stages of exposure to different therapeutic chemical substances. In addition, those sellers may intrude with the pharmacokinetics of remdesivir. For instance, Hydroxy Chloro Quine is an antidepressant drug, as an example, which appears to reduce the antimicrobial activity of remdesivir by way of impairing its intracellular metabolic activation.

Another approach that might enhance medical results might be combining remedy with particular antiretroviral tablets focusing on several approaches inside the viral fitness cycle. Although this strategy is only in the remedy of persistent HIV and HCV infections, it's uncertain whether or not that is genuine for acute SARS-CoV-2 infections.

Clinical: trials evaluating mixture remedies are needed to quantify their position in COVID-19. A Hope that in the future, this research will provide researchers with information on the ideas supplied right here for the improvement of secure and powerful corona anti-viral drugs on the grounds of their inhibitory activity that were studied and justified.

ACKNOWLEDGEMENT: This research did not receive any specific grant from the public, commercial, or non-profit funding agencies. The author acknowledges the support of the Department of Biotechnology and Bioinformatics, Bishop Heber College, Tiruchirappalli-17, in this manuscript.

CONFLICTS OF INTEREST: The author declares no conflict of interest, financial or otherwise.

REFERENCES:

1. Harapan H, Itoh N, Yufika A, Winardi W, Keam S, Te H, Megawati D, Hayati Z, Wagner AL and Mudatsir M: Coronavirus disease 2019 (COVID-19): A literature review. J Infect Public Health 2020; 13(5): 667-673.
2. Lu H, Stratton CW and Tang YW: Outbreak of pneumonia of unknown etiology in Wuhan China: the mystery and the miracle. J Med Virol 2020.
3. Hui DS, E IA, Madani TA, Ntoumi F, Kock R and Dar O: The continuing 2019- nCoV epidemic threat of novel coronaviruses to global health – the latest 2019 novel coronavirus outbreak in Wuhan, China. Int J Infect Dis 2020; 91: 264–6.
4. Gorbalenya AEA: Severe acute respiratory syndrome-related coronavirus: the species and its viruses – a statement of the Coronavirus Study Group. BioRxiv 2020.
5. Burki TK: Coronavirus in China. Lancet Respir Med 2020.
6. NHS press conference, February 4, 2020. Beijing, China. National Health Commission (NHC) of the People’s Republic of China. http://www.nhc.
7. WHO: coronavirus disease 2019 (COVID-19) situation report – 23. Geneva, Switzerland: World Health Organization; 2020.
8. Huang C, Wang Y, Li X, Ren L, Zhao J and Hu Y: Clinical features of patients infected with 2019 novel coronavirus in Wuhan. China Lancet 2020.
9. Chen N, Zhou M, Dong X, Qu J, Gong F and Han Y: Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan China: a descriptive study. Lancet 2020.
10. Burrell C, Howard C and Murphy F: Fenner and White’s medical virology. Ed 5th United States: Academic Press 2016.
11. Lu R, Zhao X, Li J, Niu P, Yang B and Wu H: Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet 2020.
12. Zhou P, Yang XL, Wang XG, Hu B, Zhang L and Zhang W: A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 2020.
13. Hughes J, Wilson M, Luby S, Gurley E and Hossain M: Transmission of human infec- tion with Nipah virus. Clin Infect Dis 2009; 49(11): 1743–8.
14. Li Q, Guan X, Wu P, Wang X, Zhou L and Tong Y: Early transmission dynam- ics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med 2020; 382(13): 1199–207.
15. Yu W, Tang G, Zhang L and Corlett R: Decoding the evolution and transmissions of the novel pneumonia coronavirus (SARS-CoV-2) using whole genomic data. China Xiv 2020 Preprint.
16. Chan JF, Yuan S, Kok KH, To KK, Chu H and Yang J: A familial cluster of pneu- monia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet 2020.
17. Kramer A, Schwebke I and Kampf G: How long do nosocomial pathogens persist on inanimate surfaces? A systematic review. BMC Infect Dis 2006; 6: 130.
18. Kampf G, Todt D, Pfaender S, Steinmann E. Persistence of coronaviruses on inanimate surfaces and its inactivation with biocidal agents. J Hosp Infect 2020.
19. Rothe C, Schunk M, Sothmann P, Bretzel G, Froeschl G and Wallrauch C: Trans- mission of 2019-nCoV infection from an asymptomatic contact in Germany. N Engl J Med 2020.
20. Kupferschmidt K: Study claiming new coronavirus can be transmitted by people without symptoms was flawed. In Science News 2020.
21. Bai Y, Yao L, Wei T, Tian F, Jin DY and Chen L: Presumed asymptomatic carrier transmission of COVID-19. JAMA 2020.
22. Huang C, Wang Y, Li X, Ren L, Zhao J and Hu Y: Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395(10223): 497–506.
23. Chu DKW, Pan Y, Cheng SMS, Hui KPY, Krishnan P and Liu Y: Molecular diag- nosis of a novel coronavirus (2019-nCoV) causing an outbreak of pneumonia. Clin Chem 2020.
24. Global surveillance for human infection with novel coronavirus (2019-nCoV). World Health Organizat 2020.
25. Bauch C and Oraby T: Assessing the pandemic potential of MERS-CoV. Lancet 2013; 382(9893): 662–4.
26. Riley S, Fraser C, Donnelly CA, Ghani AC, Abu-Raddad LJ and Hedley AJ: Trans- mission dynamics of the etiological agent of SARS in Hong Kong: impact of public health interventions. Science 2003; 300(5627): 1961–6.
27. Yang Y, Sugimoto JD, Halloran ME, Basta NE, Chao DL and Matrajt L: The transmissibility and control of pandemic influenza A (H1N1) virus. Science 2009; 326(5953): 729–33.
28. Liu Y, Gayle A, Wilder-Smith JR A. The reproductive number of COVID-19 is higher compared to SARS coronavirus. J Travel Med 2020.
29. Kucharski A and Althaus C: The role of superspreading in Middle East respiratory syndrome coronavirus (MERS-CoV) transmission. Euro Surveill 2015; 20(25) pii: 21167.
30. Chen HEA: Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records. Lancet 2020.
31. Wang D, Hu B, Hu C, Zhu F, Liu X and Zhang J: Clinical characteristics of 138 hos- pitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan. China JAMA 2020.
32. Sookaromdee P and Wiwanitkit V: Imported cases of 2019-novel coronavirus (2019-nCoV) infections in Thailand: mathematical modelling of the outbreak. Asian Pac J Trop Med 2020; 13(3): 139–40.
33. Chang, Lin M, Wei L, Xie L, Zhu G and Dela Cruz CS: Epidemiologic and clinical characteristics of novel coronavirus infections involving 13 patients outside Wuhan, China. JAMA 2020.
34. Liu W, Zhang Q, Chen J, Xiang R, Song H and Shu S: Detection of Covid-19 in children in early January 2020 in Wuhan, China. N Engl J Med 2020; 382(14): 1370–1.
35. Shen KL and Yang YH: Diagnosis and treatment of 2019 novel coronavirus infection in children: a pressing issue. World J Pediatr 2020.
36. Chan JF-W, Yuan S, Kok KH, To KKW, Chu H and Yang J: A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to- person transmission: a study of a family cluster. Lancet 2020.
37. Peiris JSM, Guan Y, Yuen KY. Severe acute respiratory syndrome. Nat Med 2004; 10(12): 88–97.
38. Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus AD and Fouchier RA: Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med 2012; 367(19): 1814–20.
39. Guan Y, Zheng BJ, He YQ, Liu XL, Zhuang ZX and Cheung CL: Isolation and characterization of viruses related to the SARS coronavirus from animals in southern China. Science 2003; 302(5643): 276–8.
40. Alagaili AN, Briese T, Mishra N, Kapoor V, Sameroff SC and Burbelo PD: Middle East respiratory syndrome coronavirus infection in dromedary camels in Saudi Arabia. mBio 2014; 5(2): 00884-00814.
41. Brennan G, Kitzman JO, Rothenburg S, Shendure J and Geballe AP: Adaptive gene amplification as an intermediate step in the expansion of virus host range. PLoSPathog 2014; 10(3): 1004002.
42. Wan Y, Shang J, Graham R, Baric RS and Li F: Receptor recognition by novel coro- navirus from Wuhan: an analysis based on decade-long structural studies of SARS. J Virol 2020; 00127-00120.
43. Li W, Moore MJ, Vasilieva N, Sui J, Wong SK and Berne MA: Angiotensin- converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 2003; 426(6965): 450–4.
44. Totura AL and Baric RS: SARS coronavirus pathogenesis: host innate immune responses and viral antagonism of interferon. CurrOpinVirol 2012; 2(3): 264–75.
45. Hamming I, Timens W, Bulthuis ML, Lely AT, Navis G and van Goor H: Tissue dis- tribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol 2004; 203(2): 631–7.
46. Wong CK, Lam CW, Wu AK, Ip WK, Lee NL and Chan IH: Plasma inflamma- tory cytokines and chemokines in severe acute respiratory syndrome. Clin Exp Immunol 2004; 136(1): 95–103.
47. Smits SL, de Lang A, van den Brand JM, Leijten LM, van IWF and Eijkemans MJ: Exacerbated innate host response to SARS-CoV in aged non-human primates. PLoS Pathog 2010; 6(2): 1000756.
48. Zhu N, Zhang D, Wang W, Li X, Yang B and Song J: A novel coronavirus from patients with pneumonia in China, 2019 N Engl J Med 2020.
49. Chen HGJ and Wang C: Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a ret- rospective review of medical records. Lancet 2020.
50. Chung M, Bernheim A, Mei X, Zhang N, Huang M and Zeng X: CT imaging features of 2019 novel coronavirus (2019-nCoV). Radiology 2020; 200230.
51. China CDC: Epidemic update and risk assessment of 2019 novel coronavirus. Chinese Center for Diseases Control and Prevention 2020.
52. Patel A and Jernigan DB: Initial public health response and interim clinical guid- ance for the 2019 novel coronavirus outbreak—United States, December 31, 2019–February 4, 2020. MMWR Morb Mortal Wkly Rep 2020; 69: 140.
53. Jin YH, Cai L, Cheng ZS, Cheng H, Deng T and Fan YP: A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version). Mil Med Res 2020; 7(1): 4.
54. Lei J, Li J, Li X and Qi X: CT imaging of the 2019 novel coronavirus (2019-nCoV) pneumonia. Radiology 2020; 200236.
55. Tang JW, Tambyah PA and Hui DSC: Emergence of a novel coronavirus causing respiratory illness from Wuhan, China. J Infect 2020.
56. Habibzadeh P and Stoneman EK: The novel coronavirus: a bird’s eye view. Int J Occup Envi Med 2020; 11(2): 65–71.
57. Organization WH: Global surveillance for human infection with novel corona- virus (2019-nCoV); 2020.
58. Gidengil C, Parker A and Zikmund-Fisher B: Trends in risk perceptions and vacci- nation intentions: a longitudinal study of the first year of the H1N1 pandemic. Am J Public Health 2012; 102: 672–9.
59. Organization WH. Clinical management of severe acute respiratory infection when novel coronavirus (2019-nCoV) infection is suspected 2020.
60. Russell C, Millar J and Baillie J: Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet 2020; 395(10223): 473–5.
61. Paules CI, Marston HD and Fauci AS: Coronavirus infections – more than just the common cold. JAMA 2020.
62. Holshue ML, DeBolt C, Lindquist S, Lofy KH, Wiesman J, Bruce H, et al. First case of 2019 novel coronavirus in the United States. The New England Journal of Medicine 2020.
63. Wang Z, Chen X, Lu Y, Chen F and Zhang W: Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment. Biosci Trends 2020.
64. Wang M, Cao R, Zhang L, Yang X, Liu J and Xu M: Remdesivir and chloro- quine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in-vitro. Cell Res 2020.
65. de Wit E, Feldmann F, Cronin J, Jordan R, Okumura A and Thomas T: Prophy- lactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection. Proceedings of the National Academy of Sciences of the United States of America 2020; 3: 20192208.
66. Liu X and Wang XJ: Potential inhibitors for 2019-nCoV coronavirus M protease from clinically approved medicines. bioRxiv 2020; 2020.2001.2029.924100.
67. Lu H: Drug treatment options for the 2019-new coronavirus (2019-nCoV). Biosci Trends 2020.
68. Mahase E: Coronavirus covid-19 has killed more people than SARS and MERS combined, despite lower case fatality rate. BMJ 2020; 368: m641.
69. Chan JFW, Lau SKP, To KKW, Cheng VCC, Woo PCY and Yuen KY: Middle East respiratory syndrome coronavirus: another zoonotic betacoronavirus causing SARS-like disease. Clin Micro Rev 2015; 28(2): 465–522.
70. Centers for Diseases Control and Prevention. Coronavirus disease 2019 (COVID- 19); 2020.
71. Wang C, Horby PW, Hayden FG and Gao GF: A novel coronavirus outbreak of global health concern. Lancet 2020.
72. Paraskevis D, Kostaki EG, Magiorkinis G, Panayiotakopoulos G, Sourvinos G and Tsiodras S: Full-genome evolutionary analysis of the novel corona virus (2019- nCoV) rejects the hypothesis of emergence as a result of a recent recombination event. Infect Genet Evol 2020; 104212.
73. Randhawa GS, Soltysiak MPM, El Roz H, De Souza CP, Hill KA, Kari L. Machine learning analysis of genomic signatures provides evidence of associations between Wuhan 2019-nCoV and bat betacoronaviruses. BioRxiv 2020.
74. Ji W, Wang W, Zhao X, Zai J and Li X: Homologous recombination within the spike glycoprotein of the newly identified coronavirus may boost cross-species trans- mission from snake to human. J Med Virol 2020.
75. Heymann DL and Shindo N: COVID-19: what is next for public health? Lancet 2020.
    

    ---

    How to cite this article:

    Akila K, Pooja B and Sharmila R: Prediction of potential inhibitors similar to remdesivir (GS-5734) against 7BTF SARS COV 2 RNA dependent RNA polymerase – an in-silico approach. Int J Pharm Sci & Res 2022; 13(11): 4628-35. doi: 10.13040/IJPSR.0975-8232.13(11).4628-35.

    ---

    All © 2022 are reserved by International Journal of Pharmaceutical Sciences and Research. This Journal licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License.